FO
PTCT icon

FT Options’s PTC Therapeutics PTCT Stock Holding History

FT Options’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$287K Buy
+14,323
New +$280K 0.43% 54
2016
Q2 		– Sell
-22,954
Closed -$168K – 396
2016
Q1 		$148K Buy
22,954
+21,379
+1,357% +$371K 0.16% 104
2015
Q4 		$51K Buy
+1,575
New +$46.4K 0.04% 153

Other funds holding PTCT

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FT Options's PTCT Position: Q3 2017 in Review

FT Options opened a new position in PTC Therapeutics (PTCT) in Q3 2017: 14,323 shares worth $287K. The stake represents 0.43% of the portfolio and ranks #54 among its holdings. This is a return to the name: FT Options previously reported a position in PTCT as recently as Q1 2016.

FT Options first reported a position in PTCT in Q4 2015 and has held it in 3 quarters since. 129 funds tracked by Wall St. Rank hold PTCT as of Q3 2017.

  • FT Options held 14,323 shares of PTC Therapeutics worth $287K as of Q3 2017.
  • PTC Therapeutics was a new FT Options position in Q3 2017.
  • PTC Therapeutics made up 0.43% of FT Options's portfolio in Q3 2017, its #54 holding.
  • FT Options first reported a position in PTC Therapeutics in Q4 2015 and has held it in 3 quarters since.
  • 129 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.